businessbriefs
9:48in productionCh. 1 · Private since day one/ 9:48 · ceiling 15 min
Companies

Serum Institute of India

1966

The world’s largest vaccine maker by volume is not a tech disruptor — it’s a high-volume, low-margin public health utility run as a private company.

Serum Institute of India is the world's largest vaccine manufacturer by volume — a fact rooted in production capacity and multilateral procurement, not IP, pricing power, or domestic dominance. Its business model depends on high-volume, low-margin contracts with global health institutions. Nothing in the source material confirms profitability, cost structure, or innovation claims. It is infrastructure masquerading as enterprise.

CompaniesVaccinesSupply chainsBiographyVaccines across the network →
Chapters & takeaways4
  1. 1:17
    Private since day one

    It is a privately owned Indian biotech firm founded in 1966 — not a startup, not a state enterprise, and not a recent entrant.

  2. 2:45
    Volume, not velocity

    Scale comes from manufacturing volume across legacy and expanded vaccine lines — not novel platforms or proprietary delivery tech.

  3. 4:59
    Beyond vaccines

    Its non-vaccine products — antisera, blood plasma, hormones — are part of its output but receive no detail on scale, regulation, or market.

  4. 6:14
    Procured, not prescribed

    Its global role is defined by procurement, not policy: WHO, UNICEF, and PAHO used its vaccines as of 2014 — a statement of supply, not influence.

Worth your time?

Yes. Study the whole thing.

4/ 5
What works
  • high-volume vaccine production
  • multilateral programme supply
  • legacy and expanded vaccine portfolio
What does not
  • profitability
  • R&D investment
  • domestic market share
  • pricing strategy
Study it if
  • public health procurement specialists
  • emerging-market manufacturing analysts
  • global health logisticians
Skip it if
  • VC investors assessing growth potential
  • IP strategists
  • biotech innovators
The written brief1 min read

What the company or idea is

Serum Institute of India is a private biotechnology and biopharmaceuticals company founded in 1966 in Pune, India, and owned by the Cyrus Poonawalla Group.

How it actually makes money

It sells vaccines and biopharmaceutical products — antisera, blood plasma, and hormone products — to global public health programmes and national immunisation systems.

What works

It manufactures at scale across multiple vaccine classes — including DPT, MMR, tetanus antitoxin, snake antivenom, influenza, meningococcal, and combination vaccines — and supplies them to major international public health programmes.

What does not

The material says nothing about pricing, margins, cost of goods sold, R&D spend, or domestic Indian market share. It does not establish whether it profits from high-income markets or relies entirely on volume-driven contracts with multilateral buyers.

What to take from it

Its significance lies in being the world’s largest vaccine manufacturer by volume — a function of production capacity, regulatory approvals, and long-term supply agreements with WHO, UNICEF, and PAHO — not innovation or IP ownership.

Is it worth your time

Yes, if you are studying how scale in vaccine manufacturing is achieved without state ownership, or how a private firm becomes infrastructure for global public health.

Same desk · Companies4 of 217
12:57
MeituanWang Xing · 2010Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
Up next in Business

Shanghai Stock Exchange

1990 · 9:55

Asia’s biggest stock exchange isn’t free—it’s run like a policy instrument.

Play nextBack to Companies
9:55